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Abstract
Background—Sustained genital tract inflammation caused by sexually transmitted infections 
(STIs) is known to increase risk of vaginal human immunodeficiency virus (HIV) infections but, to 
our knowledge, there are no non-human primate studies that have evaluated its link to rectal HIV 
acquisition.
Methods—Rhesus macaques inoculated with Chlamydia trachomatis [CT; serovars LGV-L2 and 
CT-E; n=7] or saline (n=7) received up to 20 rectal challenges twice a week of simian-human 
immunodeficiency virus (SHIVSF162p3). SHIV viremia was determined by real-time PCR and 
Chlamydia infection by APTIMA Combo 2 testing. The rectal cytokine-chemokine levels were 
evaluated by multiplex bead assays.
Results—Rectal Chlamydia infection was maintained throughout the study. We did not observe 
significant differences (p=1.0) in frequency of SHIV acquisition between the STI and control 
arms. It took fewer SHIV challenges to infect the STI animals although the difference was not 
significant (p=0.59). There were no significant differences in peak plasma viremia between STI 
and control arms (p=0.63). The association of plasma viremia with rectal shedding was 
significantly different by arm (p=0.038).
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Conclusions—In the first such study in a macaque model, we did not observe an increased risk 
of SHIV acquisition due to rectal Chlamydia co-infection. This macaque model can be further 
developed and expanded to better investigate the impact of different rectal STIs on HIV 
acquisition.
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INTRODUCTION
There were more than 1.5 million cases of Chlamydia infections reported in the United 
States in 2015, up 5.9% from 2014 (1). The number of detected cases of rectal Chlamydia 
trachomatis (CT) in men who have sex with men (MSM) increased 4-fold, attributed to 
adoption of rectal screening and frequent use of nucleic acid amplification tests (NAATs) 
instead of symptom-based screening methods (2). Similarly, in Canada, the rate of detection 
of rectal chlamydial infection among women was 44.3% higher when specific rectal 
screening in STI clinics was conducted, as opposed to testing only genitourinary samples 
(3). In addition to better screening and testing methods, there has also been an increase in 
reported anal sex in heterosexual couples (4). In response to a CT infection, the mucosal 
epithelium recruits immune cells to the site of invasion (5), thus resulting in tissue damage 
that can in turn facilitate HIV acquisition by providing ports of entry and target cells. In 
humans, CT infections have been reported to impact human immunodeficiency virus (HIV) 
susceptibility and risk of transmission (6–9). Considering the increasing rates of rectal CT 
infections and their possible contribution to the spread of HIV, we evaluated the effect of 
rectal CT infections on SHIV acquisition in a macaque model.
MATERIALS AND METHODS
Macaques, study design, and sample collection/processing
Fourteen adult Indian rhesus macaques, ages 5 to 13 years old, free of SHIV or CT infection, 
were single-housed and studied at the Centers for Disease Control and Prevention (CDC). 
All procedures (see design; Figure 1) were approved by CDC’s Institutional Animal Care 
and Use Committee in accordance with the Guide for the Care and Use of Laboratory 
Animals (published by the National Academy of Science, National Academy Press, 
Washington, DC, USA).
Chlamydia inoculations and detection
Rhesus macaques were anesthetized and inoculated rectally as previously described (10) 
with phosphate buffered saline (PBS; n=7) or two serovars of CT (n=7; table 1), serovar E 
strain E-UW/5 (1×106 IFU; 500μL volume) and LGV genotype L2 strain 434 (5×106 IFU; 
500μL), obtained from University of Washington Chlamydia Laboratory. Serovar selection 
was based on domestic prevalence and feasibility for laboratory use (TR Henning, 
unpublished). The animals were first inoculated with CT-E, and three weeks later, inoculated 
with the second serovar LGV- L2. Infections were confirmed weekly throughout the study 
from rectal secretions using the GenProbe APTIMA AC2 NAAT system. Samples that were 
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STI-negative were re-tested by Cepheid GeneXpert CT/NG (Cepheid Inc; Sunnyvale, CA) 
and an in-house multiplex RT-PCR (11). To maintain infection, all animals were boosted 
with an STI inoculation every 4 weeks. In addition, animals testing STI-negative were STI-
boosted immediately. Real-time PCR was also used to differentiate the two serovars, CT-E 
and LGV-L2, in STI-positive samples. DNA was extracted from APTIMA swabs using the 
Qiagen QIAamp DNA Mini Kit (Qiagen, Valencia, CA, USA). At study completion, 
chlamydial infections were cleared as previously described (10).
SHIV challenges and analyses of SHIV infections
The risk of SHIV acquisition was evaluated using a previously described repeat-exposure 
SHIV transmission model (12) where the animals were rectally challenged with SHIV twice 
a week up to 20 challenges (10TCID50; see study design Figure 1). Levels of plasma and 
rectal viral RNA (eluted from Merocel sponges; Medtronic, Jacksonville, FL, USA) were 
measured by reverse-transcriptase PCR (limit of detection: 50 copies/ml) (13). Infections 
were confirmed by additional in-house SHIV proviral real-time PCR assays and EIA 
detection of HIV envelope-specific antibodies (Bio-Rad HIV-1/HIV-2 Plus O EIA, Hercules, 
CA). Animals were deemed uninfected if they remained seronegative for SHIV antibodies 
and had undetectable SHIV RNA and DNA after 20 SHIV challenges.
Chemokine/cytokine measurements
Rectal secretions eluted from Merocel sponges were assessed for cytokines, chemokines, 
and other inflammatory markers (IL-1β, IL-1Ra, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12, 
IL-13, IL-15, IL-17, IL-18, G-CSF, GM-CSF, IFN-γ, TNF-a, MIP1α, MIP1β, MCP1, 
TGFA, VEGF, sCD40) using Luminex bead technology (Bioplex, Biorad, Hercules, CA) 
and a non-human primate cytokine bead panel (Millipore, Billerica, MA). Using Quick Start 
Bradford protein assay (Biorad, Hercules, CA), protein measurements were normalized 
against total soluble protein levels in the eluted secretions.
Histopathology and Immunohistochemical evaluation
At baseline (2–3 weeks before STI or control inoculation), rectal pinch biopsies (1–2mm; 
three from each animal) were collected ~5cm cranial to the anal sphincter. Biopsies were 
also collected one to two weeks after the last STI boost from all SHIV-uninfected animals, 
including the controls. Biopsies were fixed in 10% neutral buffered formalin for 72 hours 
and then stored in 70% ethanol at room temperature. Three to four weeks after the last STI 
boost, rectal tissues were collected from all SHIV-positive monkeys at necropsy. Tissue 
specimens were processed by routine paraffin histology, sectioned at 4 microns, and stained 
by hematoxylin-eosin and immunohistochemistry using an immunoalkaline phosphatase 
reaction with naphthol fast red substrate and the following primary antibodies: mouse 
monoclonal antibodies raised against CT (Washington Research Foundation, Seattle, WA), 
CD68 (Thermo Fisher Scientific; Fremont, CA), CD79a (Santa Cruz Biotechnology, Santa 
Cruz, CA), and CD20 (Dako, Carpinteria, CA), and a rabbit polyclonal antibody raised 
against CD3 (Dako). Positive control for the CT IHC comprised the same CT L2 or CT-E 
strain cultured in McCoy cells, mixed with tissue fragments and embedded in paraffin using 
the same protocol as for tissue specimens. Uninfected rhesus macaque lymph node and 
spleen tissues served as positive controls for cell marker IHC assays. Negative controls were 
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run in parallel, and consisted of tissue sections incubated with normal rabbit or mouse serum 
in place of primary antibody.
Statistical analysis
Risk for SHIV acquisition in animals with and without STI was compared using Fisher’s 
exact test. All viral loads were log transformed before analysis. The Wilcoxon rank-sum test 
was used to test if peak viremia in the two arms was statistically different. We compared the 
magnitude of the effect of plasma viral load on rectal virus shedding in animals with and 
without STI. To do this, an interaction was introduced to a mixed model for repeated 
measures. The mixed model was used to account for dependence in the data due to multiple 
observations on the same monkey. The Wilcoxon rank-sum test was also used to determine 
whether changes in cytokine measurements were statistically different relative to baseline. 
SAS version 9.3 (SAS Institute, Inc., Cary, NC) or GraphPad Prism 5 for Windows 
(GraphPad Software, San Diego, CA) was used for all statistical analyses.
RESULTS
STI infection and viremia
Productive CT infection was confirmed by GenProbe APTIMA AC2 NAAT system before 
the animals were SHIV-challenged. Swabs from the first 9 weeks were further tested to 
determine if one Chlamydia serovar dominated. Most STI-positive rectal samples showed 
serovar CT-E dominating over LGV-L2 (Table 1). After the inoculation of serovar CT-E in 
the seven STI animals at the beginning of the study (week 1), and then serovar LGV-L2 in 
week 4, it was observed in the subsequent weeks that CT-E was dominant in 6/7 macaques. 
Also, CT-E infection was sustained in 6/7 animals for up to 3 weeks (Table 1), before LGV-
L2 was introduced in week 4. One animal (#2) showed both CT serovars. It was unclear 
whether serovar domination affected the timing of SHIV infection because of the small 
sample size of infected animals; although animal #2 was infected after 4 challenges in 
presence of a mixed population (Table 1; CT-E and LGV-L2), animal #3 was infected after 2 
challenges with serovar E dominating LGV-L2, animal #1 was infected after 2 challenges 
despite temporary resolution of serovar E infection. Animal #4 became infected late, after 14 
challenges (not shown in table).
There was no significant difference in risk of SHIV acquisition between the two arms 
(Fisher’s Exact p=1.0). Four of seven animals in the STI arm (57%) became SHIV-infected, 
while 3/7 animals in the control arm (43%; figure 2) became infected. It took fewer viral 
challenges (median of 3) to infect animals in the STI arm compared to those in the control 
arm (median of 5), but the difference was not statistically significant (Table 2; Wilcoxon 
Exact p=0.59). We compared viremia in the two arms to study the effect of STI co-infection, 
and found that the difference in peak plasma viremias in the two arms was not statistically 
significant (Wilcoxon Exact p=0.63; table 2; figure 2). The levels of viremia (Table 2) in the 
STI arm reached 7.15 log10 RNA copies/mL (median: 6.5 log10 RNA copies/mL), compared 
to 7.51 log10 RNA copies/mL in the control arm (median: 6.76 log10 RNA copies/mL). To 
determine if the presence of STIs was associated with increased rectal shedding, we 
compared the levels of rectal viremia in the two arms and observed no differences (data not 
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shown). We also analyzed rectal SHIV shedding in the context of plasma viremia (Figure 
3A, B), and found that the magnitude of the effect of plasma viremia on rectal shedding was 
different by arm (p=0.038). It was observed in the scatterplot that the STI animals shed more 
virus at lower viremias (between 3.0 and 5.0 log10 RNA copies/mL; figure 3B). When we 
compared the viremias in this range, the STI animals had significantly higher rectal shedding 
(Figure 3C; p=0.049, one-sided t-test with Welch’s correction). However, this comparison 
lost statistical significance after applying a correction for repeated measures (p=0.089).
Cytokine analyses
To test our hypothesis that the levels of local inflammation would be higher in presence of 
STI infection, we compared rectal cytokine levels, including pro-inflammatory proteins, in 
both arms just before SHIV challenges. Our results showed no differences in pro-
inflammatory rectal cytokine levels (supplemental digital content 1). To ascertain the effects 
of SHIV infection on rectal inflammation, we then compared baseline (STI- and SHIV-
naïve) and post-SHIV infection cytokine levels in each arm. We found that, post-SHIV 
infection, the levels of pro-inflammatory cytokines like IL-8 (one-sided Fisher’s Exact Test; 
p=0.046) and G-CSF (p=0.025) were significantly higher in the control arm (data not 
shown); this was not observed in the STI arm. Levels of other cytokines including IL-6 
(p=0.090), TNF-α (p=0.090), and IFN-γ (p=0.070) were also higher post-SHIV infection in 
the control animals but without statistical significance.
Histopathology and immunohistochemistry
To test our hypothesis that there would be significant structural and/or inflammatory changes 
in the rectal mucosa post-CT infection, we compared tissue samples for all STI animals pre- 
and post-CT infections. We found neither significant histopathologic changes, nor CT 
antigen detected in any animal by IHC (data not shown), despite demonstration of cross-
reactivity of the antibody with the CT-E and CT-LGV-L2 strains in formalin-fixed paraffin-
embedded cell cultures, and known broad reactivity with CT in general. One STI animal had 
acute inflammation in baseline (pre-inoculation) rectal biopsies. Others showed intact 
surface mucosa and mononuclear cell populations in the lamina propria within the normal 
range for this species at all tissue collection time points (data not shown). Our findings are 
similar to those previously observed in CT-infected rhesus macaques (TR Henning, 
unpublished).
DISCUSSION
We used a previously developed co-infection macaque model (TR Henning, unpublished) 
(10) to investigate whether there would be an increased risk of rectal SHIV acquisition in the 
presence of Chlamydia co-infection. To our knowledge, this is the first such rectal SHIV 
challenge study in CT/SHIV co-infected rhesus macaques. Since superinfection with 
multiple CT serovars is quite common (14), especially among those with multiple sexual 
partners, we used two CT serovars, CT-E and LGV- L2, hypothesizing that this would render 
the local milieu more susceptible to SHIV acquisition. We employed a low virus dose 
conjecturing that the presence of CT would diminish the animals’ innate resistance to SHIV 
and accelerate the acquisition of infections in the STI arm compared to the control arm. Our 
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results showed that the risk of SHIV acquisition is not significantly enhanced by rectal CT, 
although there were 4 animals in the STI arm that were infected compared to 3 in the control 
arm. Additionally, the average number of SHIV challenges required for infection was lower 
(but not statistically significant) in the STI arm compared to the control arm. Although we 
boosted the animals regularly with CT to maintain rectal STI infection and confirmed the 
infections by multiple molecular assays, variations in Chlamydia detection are possible due 
to inadequate swabbing of the rectum leading to sub-optimal sample collection, which could 
be responsible for some negative results.
Our findings are in contrast to vaginal studies in pig-tailed macaques (15), which showed 
increased risk of intra-vaginal SHIV acquisition in presence of CT and Trichomonas 
vaginalis infection. The difference between the two studies could be the result of quicker 
resolution of local tissue inflammation in the rectum likely contributed by the absence of 
Trichomonas infection. It could also be linked to serovar CT-E dominating in the rectum 
over the more pathogenic LGV- L2 serovar. This was reflected in the rectal samples in the 
first nine weeks of our study but more data are needed to confirm these observations 
throughout the length of study. Also, we did not collect lymph node biopsies or visually 
monitor lymph node enlargement in the Chlamydia-infected animals, which might have 
indicated the spread of LGV- L2 infection. It is unlikely the number of viable LGV- L2 
inoculated in the macaque rectum was lower than that of CT-E, given that the original high-
inoculum stocks were not subjected to thawing and freezing cycles, which could impact cell 
viability. We first inoculated animals with CT-E in the rectum, and three weeks later, 
introduced the second serovar LGV- L2 so it is possible that this allowed serovar CT-E to 
establish dominance in the rectum by the time LGV- L2 was introduced. Quinn et al. had 
shown in cynomolgus macaques that LGV-L2 had induced stronger inflammatory responses 
and histopathology compared to CT-E (16). In a previous study (10) (Henning et al; 
unpublished), the authors looked at rectal cytotoxicity markers in animals infected with 
LGV- L2 only, CT-E followed by LGV- L2, or CT-E followed by treatment then LGV- L2. 
They found higher levels of IL-1β, a vital cytokine responsible for CT-related inflammatory 
mediation and pathology (17, 18) in the LGV-L2 only animals. We did not observe such 
inflammatory responses in our STI-infected animals but it is of note that we looked at local 
inflammation after CT-E inoculation and before LGV-L2, and our findings could be the 
result of CT-E causing less inflammation (16). It is also possible that the inflammatory 
responses were not higher because the CT load was insufficient despite positive NAAT 
results. Additionally, it is possible that the levels of pro-inflammatory cytokines would have 
increased with time in STI-infected animals, but this could not be verified because rectal 
samples were not collected during SHIV challenges. Compared to Quinn et al. (16) our IHC 
staining didn’t show inflammatory responses or antibodies against CT but this could be 
attributed to the difference in macaque species used. Additionally, it’s conceivable that CT 
colonized a different anatomical region like the small intestine as seen in mouse models (19) 
but this aspect is unclear in macaques. Such collection of biopsy samples was beyond the 
scope of our current study.
We were not able to conclusively demonstrate higher SHIV shedding due to rectal 
Chlamydia infections. These observations are consistent with clinical findings by Kelley et 
al. who reported no significant enhancement of HIV shedding due to rectal STI co-infection 
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(20). It is possible that rectal HIV shedding may be different from vaginal shedding since 
Lewis et al., after analyzing data from 39 different studies, concluded that the odds of 
detecting HIV-1 in the genital tract were significantly increased in the presence of CT and 
other infections (21). Our data also showed that post-SHIV infection, certain pro-
inflammatory cytokines like IL-8 and G-CSF were higher in the control arm compared to the 
baseline levels, a finding not observed in the STI arm. Although we expected high levels of 
rectal cytokines in the control animals post-SHIV infection, it was intriguing that the STI 
animals did not exhibit such a response; it might reflect elevated levels of inflammation that 
the immune system would have already mounted in chlamydial presence. Long-term effects 
of Chlamydia on cytokine levels could not be established because no rectal samples were 
collected during SHIV challenges. Although our results did not show an acute increase in 
levels of cytokines immediately post-STI infection, past studies (TR Henning, unpublished) 
have shown elevated levels several days after initial STI infection.
Overall, we found no effect of rectal Chlamydia co-infection on SHIV acquisition. Our 
results cannot be extrapolated to other rectal STIs particularly ulcerative infections, 
including syphilis or herpes, which might have an impact on risk of HIV acquisition. In light 
of increasing numbers of detected cases of rectal CT in the United States, Canada, and the 
United Kingdom, the use of an animal co-infection model for investigation of susceptibility 
and potential HIV transmission risk is relevant for both MSM populations and women who 
engage in unprotected anal intercourse. This macaque model can be further expanded to 
better investigate the impact of different rectal STIs on HIV acquisition under well-
controlled conditions that are difficult to achieve in human clinical studies.
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Our study in rhesus macaques finds no effect of rectal Chlamydia co-infection on SHIV 
acquisition.
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Study design. Evaluation of risk of HIV acquisition in CT co-infected animals. The design 
(in weeks) shows baseline collections followed by inoculation (blue arrows) with CT serovar 
E (CT-E) at week 1, and serovar LGV-L2 at week 4. The animals were boosted with CT 
(serovar E and LGV-L2) every 4 weeks to maintain infection. Starting week 5, we rectally 
challenged (red arrows) the animals with SHIV162p3 (10TCID50) twice a week up to 20 
challenges; **=cytokines measured at these points to compare local inflammation before 
and after STI inoculations; ˆ=baseline rectal biopsy collections.
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Viremia in the SHIV-infected infected STI (black) and control (orange) animals; 0=time of 
peak plasma viremia; plasma viral RNA was measured by RT PCR (limit of detection: 50 
copies/ml)
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Scatterplot showing plasma and rectal viremia (paired readings) in the two arms (A, control; 
B, STI). The data points represent readings from infected animals where both plasma and 
rectal viremia data are available; there were time points where we had insufficient quantities 
of eluted rectal secretions; C: comparison of rectal viremia in the two arms at plasma viral 
loads <5.0 and >3.0 log10 RNA copies/mL; we selected data points in this range to 
emphasize the higher levels of rectal shedding observed in the STI animals at lower viremia; 
lower limit of detection (LLD) was 50 copies/mL (log10 =1.7) so for purposes of statistical 
analyses and graphical representation, we changed all undetected viral loads to 40, 
represented as data points below the LLD; 6/8 data points (75%) were below LLD in the 
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control arm and 4/14 (29%) were below LLD in the STI arm; p=0.049, unpaired two-tailed 
t-test with Welch’s correction; p=0.089 after applying repeated measures.
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Table 2
SHIV infections and viremia in the two study arms. There were n=7 animals in each arm.
Control arm STI arm
Number of SHIV infections 3/7 4/7
Median number of SHIV challenges 5.0 3.0
Median plasma viremia (log10 RNA copies/mL) 6.75 6.49
Peak plasma viremia (log10 RNA copies/mL) 7.51 7.15
Sex Transm Dis. Author manuscript; available in PMC 2018 September 01.
